Assignee
AKESO BIOPHARMA INC
CN·9 granted patents·25 pending applications·9 citations·filing 2015–2025
Top patents by PatentIndex Score
34 records- 0194US12195527B2Anti-PD-1/VEGFA bifunctional antibody, pharmaceutical composition thereofAKESO BIOPHARMA INC·Filed 2023·Granted Jan 14, 2025·2 cites·24 claims
- 0291US10449251B2Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and usesAKESO BIOPHARMA INC·Filed 2015·Granted Oct 22, 2019·6 cites·20 claims
- 0381US2025223346A1Monoclonal antibody against nerve growth factor, and encoding gene and use thereofAKESO BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 0481US2025197487A1Anti-pd-1/vegfa bifunctional antibody, pharmaceutical composition thereof and use thereofAKESO BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 0577US12447208B2Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and usesAKESO BIOPHARMA INC·Filed 2022·Granted Oct 21, 2025·0 cites·14 claims
- 0677US11479608B2Anti-CTLA4 antibodiesAKESO BIOPHARMA INC·Filed 2017·Granted Oct 25, 2022·1 cites·24 claims
- 0775US2024025983A1Monoclonal antibody against nerve growth factor, and encoding gene and use thereofAKESO BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 0872US2025368735A1Bispecific antibody containing anti-cldn18.2 antibody, and pharmaceutical composition and use thereofAKESO BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 0972US2025376517A1Anti-cldn18.2 antibody, and pharmaceutical composition and use thereofAKESO BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1070US11291720B2Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and usesAKESO BIOPHARMA INC·Filed 2019·Granted Apr 5, 2022·0 cites·35 claims
- 1169US2025042995A1Anti-lag3 antibody, pharmaceutical composition and useAKESO BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 1268US2021340239A1Anti-pd-1/vegfa bifunctional antibody, pharmaceutical composition thereof and use thereofAKESO BIOPHARMA INC·Filed 2019·Application pending·0 cites
- 1364US12286473B2Anti-IL-1β antibody and pharmaceutical composition thereof and use of sameAKESO BIOPHARMA INC·Filed 2019·Granted Apr 29, 2025·0 cites·21 claims
- 1464US2025304703A1Anti-human il-4ra antibody and application thereofAKESO BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1563US11680095B2Monoclonal antibody against nerve growth factor, and encoding gene and use thereofAKESO BIOPHARMA INC·Filed 2019·Granted Jun 20, 2023·0 cites·21 claims
- 1663US2024117051A1Therapeutic combination and use thereofAKESO BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1763US2025129163A1Pharmaceutical composition and use thereofAKESO BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1863US2025034253A1Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1/anti-vegfa bispecific antibody, and use thereofAKESO BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1963US2026035455A1ANTI-IL-1ß ANTIBODY AND PHARMACEUTICAL COMPOSITION THEREOF AND USE OF SAMEAKESO BIOPHARMA INC·Filed 2025·Application pending·0 cites
- 2061US2025319169A2FUSION PROTEIN CONTAINING ANTI-TIGIT ANTIBODY AND TGF-ßR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOFAKESO BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 2160US2024352153A1Pharmaceutical composition and useAKESO BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 2258US2025114450A1Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereofAKESO BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 2358US2024043531A1Anti-cd47 monoclonal antibody and use thereofAKESO BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 2457US2024002504A1Anti-tigit antibody, and pharmaceutical composition and use thereofAKESO BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 2557US2024018254A1Anti-cd73 antibody and use thereofAKESO BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 2656US2024218074A1Anti-cd73 antibody and use thereofAKESO BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 2754US2023159655A1Anti-cd73 antibody and use thereofAKESO BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 2854US2023151111A1Anti-cd73-anti-pd-1 bispecific antibody and use thereofAKESO BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 2952US12595300B2Anti-human P40 protein domain antibody and use thereofAKESO BIOPHARMA INC·Filed 2020·Granted Apr 7, 2026·0 cites·20 claims
- 3052US2023027029A1Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereofAKESO BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 3150US2022324971A1Anti-cd47 monoclonal antibody and use thereofAKESO BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 3250US2023295312A1Antibody against human il-4ra and use thereofAKESO BIOPHARMA INC·Filed 2019·Application pending·0 cites
- 3347US11104734B2Anti-PD-1 monoclonal antibodyAKESO BIOPHARMA INC·Filed 2018·Granted Aug 31, 2021·0 cites·6 claims
- 3447US2021122815A1Anti-interleukin-17a antibody, pharmaceutical composition thereof and use thereofAKESO BIOPHARMA INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when AKESO BIOPHARMA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →